R L Baistrocchi, E Orti, A R de los Santos, G Di Girolamo, M L Marti, J C Pico
{"title":"Antispasmodic action of propinox on the isolated human gallbladder: possible mechanism of action.","authors":"R L Baistrocchi, E Orti, A R de los Santos, G Di Girolamo, M L Marti, J C Pico","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Propinox is an antispasmodic drug frequently used in the treatment of disorders of the gastrointestinal tract, the uterus and the gallbladder, but little is known about its relaxing activity in gallbladder tissue. The main objective of this study was to determine the antispasmodic activity of propinox, compared to other antispasmodics, in the gallbladder and to assess its binding affinity to receptor sites which may be involved in its mechanism of action. Antispasmodic activity of propinox, (-) scopolamine-n-butyl bromide, atropine and verapamil was determined in human gallbladders to reduce the risk of interspecies variability. Inhibitory activities (ED50) of carbachol-induced contraction were: atropine 5.03 x 10(-8) M > propinox 1.25 x 10(-7) M > verapamil 6.63 x 10(-6) M > (-) scopolamine-n-butyl bromide 5.4 x 10(-5) M. pD'2 for propinox was 6.94, indicating non competitive inhibition of carbachol action. Radioligand binding studies were performed to determine if the antispasmodic action of the drug involved binding to muscarinic receptors or calciumantagonist sites. The inhibition constant (Ki) of propinox for muscarinic receptors of guinea pig ileum smooth muscle, which contains a mixed M2-M3 receptor population, was 1.6 x 10(-6) M. Ki for brain muscarinic receptors (M1) was 1.0 x 10(-4) M, for cardiac receptors (M2) 1.2 x 10(-6) M and from salivary gland receptors (M3) 1.5 x 10(-6) M. For binding to the dihidropiridine calcium antagonist binding sites, Ki were: 4.9 x 10(-5) M for propinox and 2.2 x 10(-7) M for verapamil. For the phenylalkylamine binding sites Ki were: 5.0 x 10(-6) M for propinox and 3.5 x 10(-8) M for verapamil. For the benzothiacepine binding sites, Ki for propinox was 5.2 x 10(-6) M. The following may be concluded: 1.--The antispasmodic activity of propinox in isolated human gallbladder was comparatively less potent than that of atropine and more potent than those of verapamil and (-) scopolamine-n-butyl bromide. 2.--Propinox showed binding to muscarinic and calcium receptors that can be related to its antispasmodic activity; suggesting that the drug is an antispasmodic with anticholinergic and musculotropic activity. 3.--The dual mechanism of action, anticholinergic and calcium-blocking, would induce synergism of pharmacodynamic effects and minimize adverse events of pure antimuscarinic drugs or calcium antagonists.</p>","PeriodicalId":7148,"journal":{"name":"Acta physiologica, pharmacologica et therapeutica latinoamericana : organo de la Asociacion Latinoamericana de Ciencias Fisiologicas y [de] la Asociacion Latinoamericana de Farmacologia","volume":"49 3","pages":"161-9"},"PeriodicalIF":0.0000,"publicationDate":"1999-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta physiologica, pharmacologica et therapeutica latinoamericana : organo de la Asociacion Latinoamericana de Ciencias Fisiologicas y [de] la Asociacion Latinoamericana de Farmacologia","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Propinox is an antispasmodic drug frequently used in the treatment of disorders of the gastrointestinal tract, the uterus and the gallbladder, but little is known about its relaxing activity in gallbladder tissue. The main objective of this study was to determine the antispasmodic activity of propinox, compared to other antispasmodics, in the gallbladder and to assess its binding affinity to receptor sites which may be involved in its mechanism of action. Antispasmodic activity of propinox, (-) scopolamine-n-butyl bromide, atropine and verapamil was determined in human gallbladders to reduce the risk of interspecies variability. Inhibitory activities (ED50) of carbachol-induced contraction were: atropine 5.03 x 10(-8) M > propinox 1.25 x 10(-7) M > verapamil 6.63 x 10(-6) M > (-) scopolamine-n-butyl bromide 5.4 x 10(-5) M. pD'2 for propinox was 6.94, indicating non competitive inhibition of carbachol action. Radioligand binding studies were performed to determine if the antispasmodic action of the drug involved binding to muscarinic receptors or calciumantagonist sites. The inhibition constant (Ki) of propinox for muscarinic receptors of guinea pig ileum smooth muscle, which contains a mixed M2-M3 receptor population, was 1.6 x 10(-6) M. Ki for brain muscarinic receptors (M1) was 1.0 x 10(-4) M, for cardiac receptors (M2) 1.2 x 10(-6) M and from salivary gland receptors (M3) 1.5 x 10(-6) M. For binding to the dihidropiridine calcium antagonist binding sites, Ki were: 4.9 x 10(-5) M for propinox and 2.2 x 10(-7) M for verapamil. For the phenylalkylamine binding sites Ki were: 5.0 x 10(-6) M for propinox and 3.5 x 10(-8) M for verapamil. For the benzothiacepine binding sites, Ki for propinox was 5.2 x 10(-6) M. The following may be concluded: 1.--The antispasmodic activity of propinox in isolated human gallbladder was comparatively less potent than that of atropine and more potent than those of verapamil and (-) scopolamine-n-butyl bromide. 2.--Propinox showed binding to muscarinic and calcium receptors that can be related to its antispasmodic activity; suggesting that the drug is an antispasmodic with anticholinergic and musculotropic activity. 3.--The dual mechanism of action, anticholinergic and calcium-blocking, would induce synergism of pharmacodynamic effects and minimize adverse events of pure antimuscarinic drugs or calcium antagonists.
丙炔醇是一种常用于治疗胃肠道、子宫和胆囊疾病的抗痉挛药物,但对其在胆囊组织中的松弛作用知之甚少。本研究的主要目的是确定丙炔醇与其他抗痉挛药相比在胆囊中的抗痉挛活性,并评估其与受体位点的结合亲和力,这可能涉及其作用机制。测定丙炔醇、(-)东莨菪碱-正丁基溴、阿托品和维拉帕米在人胆囊中的抗痉挛活性,以降低种间变异性的风险。丙醇诱导的收缩抑制活性(ED50)为:阿托品5.03 × 10(-8) M >丙醇1.25 × 10(-7) M >维拉帕米6.63 × 10(-6) M >(-)东莨菪碱-正丁基溴5.4 × 10(-5) M. pD′2为6.94,表明丙醇的作用具有非竞争性抑制作用。进行了放射性配体结合研究,以确定药物的抗痉挛作用是否涉及与毒蕈碱受体或钙激动剂位点的结合。抑制常数(Ki) propinox豚鼠回肠平滑肌的毒蕈碱的受体,它包含一个混合M2-M3受体人口,1.6 x 10 (6) M . Ki对大脑毒蕈碱的受体(M1)是1.0 x 10(4)米,心脏受体(M2) 1.2 x 10 (6) M和唾腺受体(M3) 1.5 x 10 (6) M .绑定到dihidropiridine钙拮抗剂结合位点,Ki: 4.9 x 10(5)米propinox和维拉帕米的2.2 x 10(7)米。苯烷基胺结合位点Ki为:丙醇5.0 × 10(-6) M,维拉帕米3.5 × 10(-8) M。对于苯并噻唑平结合位点,丙醇的Ki值为5.2 × 10(-6) m。——丙醇在离体人胆囊中的抗痉挛活性相对于阿托品弱,而比维拉帕米和(-)东莨菪碱-正丁基溴更强。2.丙醇显示与毒蕈碱和钙受体结合,这可能与其抗痉挛活性有关;提示该药是一种具有抗胆碱能和增肌活性的抗痉挛药。3.-双重作用机制,抗胆碱能和钙阻断,将诱导药效学效应的协同作用,并最大限度地减少纯抗毒蕈碱药物或钙拮抗剂的不良事件。